Number of the records: 1
Cyclin-dependent kinase inhibitors as anticancer drugs
- 1.
SYSNO ASEP 0359286 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Článek ve WOS Title Cyclin-dependent kinase inhibitors as anticancer drugs Author(s) Kryštof, Vladimír (UEB-Q) RID, ORCID
Uldrijan, S. (CZ)Number of authors 2 Source Title Current Drug Targets. - : Bentham Science Publishers - ISSN 1389-4501
Roč. 11, č. 3 (2010), s. 291-302Number of pages 12 s. Language eng - English Country NL - Netherlands Keywords CDK ; protein kinase ; inhibitor Subject RIV CE - Biochemistry R&D Projects GA204/08/0511 GA ČR - Czech Science Foundation (CSF) GA301/08/1649 GA ČR - Czech Science Foundation (CSF) LC06077 GA MŠMT - Ministry of Education, Youth and Sports (MEYS) CEZ AV0Z50380511 - UEB-Q (2005-2011) UT WOS 000274419800004 Annotation Poor therapeutic outcomes and serious side effects, together with acquired resistance to multiple drugs, are common problems of current cancer therapies. Therefore, there is an urgent need for new cancer-targeted drugs, which has led (inter alia) to the development of molecules that can specifically inhibit cyclin-dependent kinases (CDKs). In addition to their cell cycle regulatory functions, CDKs, especially CDK7 and CDK9, play important roles in the regulation of RNA polymerase II-mediated transcription. Here, we report on progress in the preclinical development of CDK inhibitors and their anticancer activities. Special attention is paid to the action mechanisms of the pan-specific CDK inhibitors flavopiridol and roscovitine, which have already entered phase II clinical trials as treatments for various tumours. Workplace Institute of Experimental Botany Contact David Klier, knihovna@ueb.cas.cz, Tel.: 220 390 469 Year of Publishing 2011
Number of the records: 1